A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea

BACKGROUND: This phase III trial compared the efficacy and safety of gemcitabine plus capecitabine (GemCap) versus single-agent gemcitabine (Gem) in advanced pancreatic cancer as first-line chemotherapy. METHODS: A total of 214 advanced pancreatic cancer patients were enrolled from 16 hospitals in S...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Medicine (Baltimore)
Main Authors: Lee, Hee Seung, Chung, Moon Jae, Park, Jeong Youp, Bang, Seungmin, Park, Seung Woo, Kim, Ho Gak, Noh, Myung Hwan, Lee, Sang Hyub, Kim, Yong-Tae, Kim, Hyo Jung, Kim, Chang Duck, Lee, Dong Ki, Cho, Kwang Bum, Cho, Chang Min, Moon, Jong Ho, Kim, Dong Uk, Kang, Dae Hwan, Cheon, Young Koog, Choi, Ho Soon, Kim, Tae Hyeon, Kim, Jae Kwang, Moon, Jieun, Shin, Hye Jung, Song, Si Young
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2017
Assuntos:
4500
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5228666/
https://ncbi.nlm.nih.gov/pubmed/28072706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000005702
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados